Advances in bladder cancer biology and therapy

Tran, Linda L.; Xiao, Jin-Fen; Agarwal, Neeraj; Duex, Jason E.; Theodorescu, Dan

doi:10.1038/s41568-020-00313-1

Cited by 419 publications

(407 citation statements)

References 228 publications

Supporting

Mentioning

355

Contrasting

Unclassified

Order By: Relevance

“…LumNS is strongly related to micropapillary morphology and CIS. LumU tumors are characterized by enrichment in genomic instability and mutations in the genes encoding for the APOBEC protein family and the highest levels of TP53 and ERCC2 mutations, associated with sensitivity to chemotherapeutic agents (41)(42)(43)(44). Stroma-rich tumors show high expression of endothelial and myofibroblastic gene signatures, T, and B cell markers.…”

Section: Muscle Invasive Bladder Cancermentioning

confidence: 99%

“…The use of immunohistochemistry to reveal the molecular profile is an appealing strategy, given its potential applicability in routine pathology practice. However, this approach is not clinically validated (39)(40)(41)(42)(43)(44)(45). Despite some progress in unraveling the molecular complexities of MIBC over the last decade, there is still no readily available molecular biomarker of neoadjuvant chemotherapy response.…”

Section: Biomarkers Of Response To Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer

Ulamec

Murgić

Novosel

et al. 2021

ama

View full text Add to dashboard Cite

This review aims to emphasize new insights into the diagnosis, classification, and therapy of bladder cancer (BC). Bladder cancer is a heterogeneous, complex disease on a morphological, molecular, diagnostic, and prognostic level. Cancer stage is still the most important attribute for prognosis and treatment, while early detection with optimal and rapid individual therapeutic and surveillance approach is crucial. The vast majority of patients have a superficial, non-muscle-invasive tumor associated with a good prognosis after resection and adjuvant intravesical maintenance immuno or chemotherapy if needed. On the other hand, muscle-invasive bladder cancer is a highly aggressive disease with high morbidity and mortality. However, it has become a model for oncology success over the last five years with many available targeted therapeutic modalities. Metastatic BC is now amenable to multimodal treatment combining cystectomy and neoadjuvant chemotherapy and immunotherapy and is a target for precision medicine.Conclusion. A new molecular taxonomy for bladder cancer has been proposed and provided insight into BC’s carcinogenesis, with some possible effects on therapy decisions. However, this classification is still not applicable in routine clinical practice. It opens new questions regarding the interplay between tumor genetic signature, intratumoral heterogeneity, therapy implications, and tumor progression.

show abstract

Section: Muscle Invasive Bladder Cancermentioning

confidence: 99%

Section: Biomarkers Of Response To Chemotherapymentioning

confidence: 99%

New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer

Ulamec

Murgić

Novosel

et al. 2021

ama

View full text Add to dashboard Cite

show abstract

“…Among the urological cancers, prostate cancer (PCa), bladder cancer (BCa) and kidney cancer are the three most common (1). Although treatment strategies have improved significantly, the recurrence rate remains high, and advanced tumour status tends to be associated with unfavourable outcomes (2)(3)(4). Therefore, much research in the last one to two decades has been dedicated to exploring potential biomarkers and identifying promising options for patients with urological malignancies.…”

Section: Introductionmentioning

confidence: 99%

Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers

Yang

Zheng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The incidence of urological cancer has been gradually increasing in the last few decades. However, current diagnostic tools and treatment strategies continue to have limitations. Substantial evidence shows that long noncoding RNAs (lncRNAs) play essential roles in carcinogenesis and the progression, treatment response and prognosis of multiple human cancers, including urological cancers, gastrointestinal tumours, reproductive cancers and respiratory neoplasms. LncRNA small nucleolar RNA host genes (SNHGs), a subgroup of lncRNAs, have been found to be dysregulated in tumour cell biology. In this review, we summarize the impacts of lncRNA SNHGs in urological malignancies and the underlying mechanisms.

show abstract

“…4 A non-invasive, patient-friendly, cost-effective, and rapid diagnostic method for BC is urgently needed. 5 Bladder's cancerous may cause the slough of cancer cells in the surface, and contaminate the urine in it. 6 Therefore, careful investigation of the composition of urine, such as metabolic small molecules can potentially provide a non-invasive urinary cancer/disease diagnosis method 7 .…”

Section: Introductionmentioning

confidence: 99%

Rapid Mass Spectrometric Diagnosis of Bladder Cancer via Urine Carbonyl Metabolic Fingerprints

Nie

Jiang

et al. 2021

Preprint

View full text Add to dashboard Cite

The diagnosis of bladder cancer (BC) is currently based on cystoscopy, which is invasive and expensive. Here, we described a non-invasive, low-cost BC diagnosis method based on a desorption, separation, and ionization mass spectrometry platform (DSI-MS) that adopts N, N- Dimethylethylenediamine (DMED) as a differential labeling reagent. The DSI-MS platform avoids the interferences from intra- and/or inter-samples, while the DMED increases detection sensitivity and distinguishes carboxyl, aldehyde, and ketone groups from untreated samples. Carbonyl metabolic fingerprints of urine from 28 BC patients and 38 controls were portrayed and significant differences of some potential biomarkers were observed. The mechanisms of the changes have been discussed. Logistic regression (LR) was applied to discriminate BC from controls and an accuracy of 87% was achieved. We believe this patient-friendly method provides a hopeful approach for BC rapid point-of-care diagnostic.

show abstract

Advances in bladder cancer biology and therapy

Cited by 419 publications

References 228 publications

New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer

New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer

Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers

Rapid Mass Spectrometric Diagnosis of Bladder Cancer via Urine Carbonyl Metabolic Fingerprints

Contact Info

Product

Resources

About